IFNG and ganglioneuroma: IFN-γ has been used as an adjunctive treatment for immunocompromised patients (such as leukemia patients, HIV patients, and transplant patients) with invasive fungal infections.[34,35] This may be the reason for fungal-BSI patients have significantly higher levels than GN-BSI and GP-BSI patients.